Global Search | Novartis United States of America

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 696 results

Media Release / Oct 08, 2019

Novartis receives FDA approval for BEOVU®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept

In two head-to-head clinical trials, patients on BEOVU (brolucizumab-dbll) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of…
Media Release / Oct 08, 2019

Novartis STEP Program™ now accepting submissions for proposals that address unmet patient needs in cancer biomarker testing
Media Release / Oct 08, 2019

Novartis receives FDA approval for BEOVU®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
Media Release / Oct 02, 2019

Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum

- Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA)(1)- Novartis plans FDA submission…
Media Release / Oct 02, 2019

Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
Media Release / Sep 19, 2019

AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1

BASEL, Switzerland, Sept. 19, 2019 /PRNewswire/ -- New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age‑appropriate…
Media Release / Sep 19, 2019

AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1
Media Release / Sep 02, 2019

Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings

- Results from PROVE-HF trial show significant improvements in measures of cardiac structure and function at six months and one year in heart failure with reduced ejection fraction (HFrEF) patients;(…
Media Release / Sep 02, 2019

Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings
Media Release / Jul 22, 2019

Novartis Teams Up With Celebrity Interior Designer Nate Berkus To Launch My Home In Sight, A Program Empowering People With Wet AMD To Live More Independently At Home

- My Home in Sight, developed in partnership with six leading patient advocacy organizations, provides five key principles of adapting spaces in the home to support those impacted by wet AMD and…

‹ Previous page
1
…
21
22
23
24
25
26
27
…
70
› Next page